Symphogen A/S Issued Patent Covering Sympress(TM) Technology For Manufacturing Recombinant Polyclonal Antibodies

COPENHAGEN, Denmark--(BUSINESS WIRE)--Sept. 11, 2006--Symphogen announced today that the European Patent Office issued European Patent number 1,583,830 titled, "Method for manufacturing recombinant polyclonal proteins". The patent broadly covers Symphogen's proprietary method of manufacturing recombinant human polyclonal antibodies (pAb) with the Sympress(TM) manufacturing platform. In addition to covering Symphogen's proprietary gene technology for polyclonal antibody production, the patent also covers use of pAb manufacturing cell lines and Symphogen's polyclonal antibody expression libraries.
MORE ON THIS TOPIC